Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAI FUDR/Dexamethasone + GemOx vs GemOx in Unresectable Intrahepatic Cholangiocarcinoma
NCT04891289Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2021
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of floxuridine in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival at 2 years. Started May 2021; status: recruiting.
02
Drugs
floxuridine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04891289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891289.